Showing results (161-170 of 174) with videos related to

Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trialKarim Fizazi, Francois Lesaunier, Remy Delva, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2015
Critical role of Chlamydomonas reinhardtii ferredoxin-5 in maintaining membrane structure and dark metabolismWenqiang Yang, Tyler M Wittkopp, Xiaobo Li, et al.
Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer PatientsAnne de la Rochefordiere, Maud Kamal, Anne Floquet, et al.
The Lancet. Oncology|June 2, 2015
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trialKarim Fizazi, Laura Faivre, François Lesaunier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2026
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12Cécile Vicier, Farah Erdogan, Nedjla Allouache, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2014
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)Gwenaelle Gravis, Patricia Marino, Florence Joly, et al.
The Lancet. Oncology|January 12, 2013
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialGwenaelle Gravis, Karim Fizazi, Florence Joly, et al.
Clinical Genitourinary Cancer|June 1, 2023
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 TrialValentina Orlando, Damien Drubay, Pernelle Lavaud, et al.
European Urology|October 4, 2014
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic ModelGwenaelle Gravis, Jean-Marie Boher, Karim Fizazi, et al.
Pageof 18